drugset / Trial / NCT03777085
Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)
RandomizedParallel-groupDouble-blindTreatment
Summary
The Purpose of This Study is to Compare the Efficacy, Safety, Immunogenicity and Pharmacokinetics between TQB2303 and Rituximab in Combination With CHOP in Previously Untreated Patients with Diffuse Large B-cell Lymphoma
Timeline
- Start
- 2019-01-10
- Primary completion
- 2020-12-30
- Completion
- 2020-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Subject | TQB2303 | Unknown | 375 mg/m2 | Intravenous |